Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleIllustrated Post

Dual Role for l-[Methyl-11C]-Methionine PET in Acromegaly: Confirming Remission and Detecting Recurrence

Linus Haberbosch, Daniel Gillett, James MacFarlane, Olympia Koulouri, Knut Mai, Joachim Spranger, Richard Mannion, Heok Cheow, Jonathan Jones and Mark Gurnell
Journal of Nuclear Medicine February 2024, 65 (2) 327-328; DOI: https://doi.org/10.2967/jnumed.123.266446
Linus Haberbosch
1Wellcome-MRC Institute of Metabolic Science and Addenbrooke’s Hospital, Cambridge, United Kingdom; and
2Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Gillett
1Wellcome-MRC Institute of Metabolic Science and Addenbrooke’s Hospital, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James MacFarlane
1Wellcome-MRC Institute of Metabolic Science and Addenbrooke’s Hospital, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olympia Koulouri
1Wellcome-MRC Institute of Metabolic Science and Addenbrooke’s Hospital, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Knut Mai
2Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim Spranger
2Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Mannion
1Wellcome-MRC Institute of Metabolic Science and Addenbrooke’s Hospital, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heok Cheow
1Wellcome-MRC Institute of Metabolic Science and Addenbrooke’s Hospital, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Jones
1Wellcome-MRC Institute of Metabolic Science and Addenbrooke’s Hospital, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Gurnell
1Wellcome-MRC Institute of Metabolic Science and Addenbrooke’s Hospital, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Molecular imaging using the amino acid PET tracer l-[methyl-11C]-methionine (11C-Met PET) is emerging as an important addition to the armamentarium of clinicians treating pituitary disease. In acromegaly cases, 11C-Met PET can accurately localize sites of residual tumors to guide (further) surgery or radiotherapy (1,2). However, 11C-Met PET can also help confirm remission. Here, we illustrate both roles in a single patient.

A 31-y-old woman with recently diagnosed acromegaly (insulin-like growth factor 1, 103.0 nmol/L; upper limit of normal, 45.0) underwent endoscopic transsphenoidal surgery for a macroadenoma (21 mm). Gross total resection was achieved, with complete biochemical remission (insulin-like growth factor 1, 21.3 nmol/L; nadir growth hormone, 0.33 μg/L). Although postoperative MRI suggested a possible right-sided tumor remnant, 11C-Met PET demonstrated only physiologic uptake in the remaining normal gland (Fig. 1A).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

MRI, 11C-Met PET, and coregistered images during initial remission (A), at recurrence (B), and after successful repeat surgery (C). Normal pituitary gland (demonstrating typical variability in uptake between scans) is indicated by white arrows; recurrence (visually appreciated on second scan only) is indicated by yellow arrows. (A) MRI showing indeterminate appearance in right sella but with 11C-methionine uptake confined to residual normal gland in left side of sella. (B) MRI unchanged despite disease relapse; 11C-Met PET reveals discrete, new focus of 11C-methionine uptake in right sella. (C) Normalization of insulin-like growth factor 1 after repeat surgery correlates with absence of right-sided tracer uptake. Coronal MRI of T1-weighted fast-spoiled gradient echo images: repetition time, 11.5 ms; echo time, 4.2 ms; isotropic voxel spacing of 1 mm × 1 mm (256 × 256 matrix size) × 1 mm (slice thickness). 11C-Met PET static images acquired on GE Discovery-690 20–40 min after administration of 11C-Met. Ordered-subset expectation maximization reconstruction: attenuation correction, time-of-flight, point-spread function, 3 iterations, 24 subsets, and gaussian postprocessing filter (3.2 mm in 2011, 2 mm in 2020–2021). coreg = coregistered.

Nine years later, the patient experienced clinical and biochemical recurrence (insulin-like growth factor 1, 44.9 nmol/L; upper limit of normal, 35.5; nadir growth hormone, 1.75 μg/L). However, the contemporaneous MRI was unchanged. Therefore, a second 11C-Met PET study was performed, which revealed a new focus of radiotracer uptake in the right sella adjacent to, but distinct from, the normal gland (Fig. 1B). The patient underwent repeat surgery, and the tumor was resected from the site identified on the 11C-Met PET scan. The patient reentered remission (insulin-like growth factor 1, 15.6 nmol/L; upper limit of normal, 28.0; nadir growth hormone, <0.05 μg/L), with repeat 11C-Met PET demonstrating uptake only in the residual normal gland (Fig. 1C), consistent with otherwise preserved pituitary function. This report therefore illustrates the dual role of 11C-Met PET in acromegaly, confirming remission and detecting recurrence (1).

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Sep. 28, 2023.

  • © 2024 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.
    1. Koulouri O,
    2. Kandasamy N,
    3. Hoole AC,
    4. et al
    . Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. Eur J Endocrinol. 2016;175:485–498.
  2. 2.
    1. Bashari WA,
    2. Senanayake R,
    3. Koulouri O,
    4. et al
    . PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. Neurosurg Focus. 2020;48:E8.
  • Received for publication August 1, 2023.
  • Revision received September 12, 2023.
SNMMI

© 2025 SNMMI

Powered by HighWire